8 unknown. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 8 |
| Phase 1 | 5 | Unknown 5 |
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML anti-CD33 CAR-NK cells - Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-12-06 |
| Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy Inecalcitol, Placebo Oral Tablet - Acute Myelogenous Leukemia | Phase 2 | Unknown | Hybrigenics Corporation | 110 | 2016-06-01 | 2017-07-02 |
| Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine - Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Mateon Therapeutics | 105 | 2015-10-01 | 2018-06-04 |
| The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). Azacitidine, azacitidine + lenalidomide - Myelodysplastic Syndrome, Acute Myelogenous Leukemia | Phase 2 | Unknown | Nordic MDS Group | 72 | 2012-03-01 | 2012-03-16 |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) - Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 20 | 2011-12-01 | 2012-01-20 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PR104 - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Proacta, Incorporated | 50 | 2010-01-01 | 2012-08-31 |
| Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM) cell therapy product, injection of the cell therapy product - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Unknown | Nantes University Hospital | 5 | 2009-11-01 | 2016-07-26 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Tacrolimus and MMF - Multiple Myeloma, Lymphoma | Phase 2 | Unknown | Colorado Blood Cancer Institute | 40 | 2004-03-01 | 2008-02-08 |
Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia, Myeloid (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Leukemia (7) · Bone Marrow Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1)
Azacitidine (1) · Cytarabine (1) · Lenalidomide (1) · Sensitivity and Specificity (1) · Tacrolimus (1) · inecalcitol (1)
Colorado Blood Cancer Institute (1) · Hybrigenics Corporation (1) · Jules Bordet Institute (1) · Mateon Therapeutics (1) · Nantes University Hospital (1) · Nordic MDS Group (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · Proacta, Incorporated (1)
United States (4) · France (2) · Belgium (1) · China (1) · Sweden (1)
Jean-Francois Dufour-Lamartinie, MD (1) · Peter A McSweeney, MD (1) · Philippe Martiat, MD PhD (1)
PMID 25682597, PMID 28054442, PMID 31551349, PMID 34152898, PMID 39921387